

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Masaya YAMANOUCI et al. Conf.:
Appl. No.: NEW Group: Unassigned
Filed: March 26, 2004 Examiner: Unassigned
For: THERAPEUTIC AGENTS FOR RENAL DISEASESAND
METHOD FOR SCREENING THE SAME

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 26, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form, attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form is requested since any patents, publications, or other information which are listed on the PTO-1449 form but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No.
09/979,765

U.S. Filing Date
November 27, 2001

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32868

Raymond C. Stewart, #21,066

✓
RCS/KJR/bsh
0020-4935PUS2

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s) : ☒ PTO-1449

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 02/12/2004)

Form PTO-1449				ATTY. DOCKET NO. 0020-4935PUS2		APPLICATION NO. NEW		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT Masaya YAMANOUCI et al.				
				FILING DATE March 26, 2004		GROUP Unassigned		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	US 2002/0182197	A1	2002-12-05	Black et al.				
	US 6,353,009	B1	2002-03-05	Fujiwara et al.				
	US							
	US							
FOREIGN PATENT DOCUMENTS								
Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
JP	11-242026	A	1999-09-07	JAPAN				
EP	604983	A1	1994-07-06	EPO				
EP	1043587	A1	2000-10-11	EPO				
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)								
	Burris, Molecular Endocrinology, Vol. 13, No. 3, pp.410-417 (1999)							
	Buckingham, Diabetes, Vol. 47, pp.1326-1334 (1998)							
	Veerkamp et al., Prog. Lipid Res., 34, pp. 17-52 (1995)							
	Lehmann et al., J. Biol. Chem., 270, pp. 12953-12956 (1995)							
	Willson et al., J. Med. Chem., 39, pp. 665-668 (1996)							
	R.C. Anderson, Current Pharmaceutical Design, 4, pp. 1-16 (1998)							
	D. Portilla, Kidney International, 52, pp. 429-437 (1997)							
	Meunier-Durmort, Biochem. J., Vol. 319, No. 2, pp.483-487 (1996)							
EXAMINER				DATE CONSIDERED				
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								